Compare Stocks

Absolute Software Corp. engages in the provision of cloud-based service that supports the management and security of computing devices, applications, and data for a variety of organizations. Its solutions includes education, financial services, general date protection regulations (GDPR) compliance, government, healthcare, professional services, and technology solutions such as Absolute for Android, and Absolute for Chromebook. The company was founded on November 24, 1993 and is headquartered in Vancouver, Canada.

Amerisur Resources plc engages in exploration and production of oil and gas assets in Colombia and Paraguay. It has assets around the OBA pipeline and also across the wider Putumayo region, with 11 blocks in total covering 984,000 hectares gross. Amerisur Resources Plc was incorporated in 2000 and is based in Cardiff, the United Kingdom.

Foxtons Group plc, an estate agency, provides services to the residential property market in the United Kingdom. The company operates through three segments: Lettings, Sales, and Financial Services. The Lettings segment engages in letting and management of residential properties. The Sales segment sells residential properties. The Financial Services segment offers mortgages and related products. Foxtons Group plc was founded in 1981 and is headquartered in London, the United Kingdom.

Lonmin Plc explores, mines, refines, and markets platinum group metals in South Africa, the Americas, Asia, and Europe. The company explores for platinum, palladium, rhodium, iridium, ruthenium, and gold, as well as chrome, nickel, copper, and cobalt deposits. Its flagship property is the Marikana mine located on the Western Limb of the Bushveld igneous complex in South Africa. In addition, the company holds 100% interest in Pandora mine. The company was founded in 1909 and is headquartered in Melrose North, South Africa.

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.